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Usher syndrome type II (USH2) is a genetically heterogeneous autosomal recessive disorder with at least three
genetic subtypes (USH2A, USH2B, and USH2C) and is classified phenotypically as congenital hearing loss and
progressive retinitis pigmentosa. The VLGR1 (MASS1) gene in the 5q14.3-q21.1 USH2C locus was considered a
likely candidate on the basis of its protein motif structure and expressed-sequence-tag representation from both
cochlear and retinal subtracted libraries. Denaturing high-performance liquid chromatography and direct sequencing
of polymerase-chain-reaction products amplified from 10 genetically independent patients with USH2C and 156
other patients with USH2 identified four isoform-specific VLGR1 mutations (Q2301X, I2906FS, M2931FS, and
T6244X) from three families with USH2C, as well as two sporadic cases. All patients with VLGR1 mutations are
female, a significant deviation from random expectations. The ligand(s) for the VLGR1 protein is unknown, but
on the basis of its potential extracellular and intracellular protein-protein interaction domains and its wide mRNA
expression profile, it is probable that VLGR1 serves diverse cellular and signaling processes. VLGR1 mutations
have been previously identified in both humans and mice and are associated with a reflex-seizure phenotype in
both species. The identification of additional VLGR1 mutations to test whether a phenotype/genotype correlation
exists, akin to that shown for other Usher syndrome disease genes, is warranted.
Usher syndrome is a clinically and genetically hetero-
geneous recessive disease with three clinical subtypes.
The subtypes are differentiated on the basis of the se-
verity of hearing loss and presence or absence of vestib-
ular abnormalities. Patients with Usher syndrome type
I (USH1) present with profound congenital hearing loss,
vestibular areflexia (in most cases), and a progressive
retinal degeneration, with impaired night vision and de-
creased visual fields diagnosed as retinitis pigmentosa
(RP). Usher syndrome type II (USH2 [MIM 276900])
have a moderate-to-severe sensorineural hearing loss
that is stable in most cases, normal vestibular function,
and RP, whereas patients with type III (USH3) present
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a moderate sensorineural hearing loss with progression
to acquired deafness, progressive vestibular dysfunction,
and RP. Currently, 11 loci have been identified for Usher
syndrome (Kimberling et al. 1990, 1992; Kaplan et al.
1992; Smith et al. 1992; Sankila et al. 1995; Wayne et
al. 1996, 1997; Chaib et al. 1997; Hmani et al. 1999;
Pieke-Dahl et al. 2000; Mustapha et al. 2002); families
that do not link to the known loci indicate additional
genes exist. Of the 11 loci, 7 genes have been found with
Usher syndrome mutations (Weil et al. 1995, 2003; Eudy
et al. 1998; Bitner-Glindzicz et al. 2000; Verpy et al.
2000; Ahmed et al. 2001; Alagramam et al. 2001; Bolz
et al. 2001; Bork et al. 2001; Joensuu et al. 2001).
Previously, we had localized the USH2C gene to a 20-
cM region on chromosome 5q14.3–5q21.1 (Pieke-Dahl
et al. 2000). Reference mRNAs in this linkage interval
were obtained from the UCSC Genome Browser Web site
and were prioritized for candidate-gene mutation screen-
ing. The very large G-coupled receptor gene (VLGR1)
was considered a likely USH2C candidate (Burgess 2001;
Staub et al. 2002), with EST representation in bothhuman
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Figure 1 Segregation of VLGR1 mutations Q2301X, M2931FS, I2906FS, and T6244X in families 735, 964, and 1848 (with USH2C).
A, Paternal inheritance of Q2301X in family 1848 is shown by agarose-gel electrophoresis of exon 31 PCR product XmnI digests. Q2301X
mutation is a 6901 CrT transition, 33 bp on the 3′ end of the alternate exon 31 splice donor, affecting only the VLGR1b mRNA isoform (fig.
2a). Shown here are sequence electropherograms from the heterozygous family 1848 proband (HET), an apparent Q2301X homozygote, and
wild-type (WT) BAC clone RP11-29K14, with sequence and amino acid translation differences (arrows). The Q2301X homozygote was the
result of a brother-sister incestuous union, whereas another singleton case was a Q2301X/occult heterozygote (data not shown; table 1). B,
Maternal inheritance of M2931FS in family 964 is shown by agarose-gel electrophoresis of exon 39 PCR product NcoI digests. Sequence
electropherograms of the WT and the cloned M2931FS allele show 8790delC in exon 39 (arrows). This deletion causes a 10-codon frameshift.
ending with a TAG stop encoded by the last 3 bases of exon 39, affecting VLGR1b. C, Maternal inheritance of I2906FS in family 1848 by
DHPLC of exon 38 PCR products. Sequence comparison of the cloned I2906FS mutation shows an 8716–17insAACA (arrows) causing a
frameshift of 5 codons and ending with a TGA stop 1 bp short of the 3′ end of exon 38, affecting VLGR1b. D, Paternal inheritance of Y6244X
detected by DHPLC of exon 89 PCR products. A 19-bp deletion brings a TAG stop codon immediately in-frame. Y6244X removes 63 amino
acids from the COOH end of VLGR1a and VLGR1b. The putative maternal and paternal mutations in family 735 and family 964 have not
been identified.
fetal retina and cochlea (obtained from the National Eye
Institute Gene Bank Web site) subtracted libraries. Use of
the conserved domain architecture retrieval (CDART)
tool on VLGR1 (Geer et al. 2002) revealed a motif ar-
chitecture similar to the cadherin superfamily of integral
membrane proteins. This superfamily includes CDH23
and PCDH15, which are the genes mutated in USH1D
(MIM 601067) and USH1F (MIM 602083), respectively.
In addition, VLGR1 and theUSH2A gene product usherin
exhibit a high degree of similarity in their respective pen-
traxin (PTX) homology domains. On the basis of this
evidence, we sought to implicate the VLGR1 gene in the
pathogenesis of USH2.
Denaturing high-performance liquid chromatography
(DHPLC) and direct sequencing were used to detect mu-
tations in PCR-amplified genomic DNA from 10 pro-
bands with USH2C (MIM 605472) for 90 VLGR1 ex-
ons. The 10 affected probands were members of families
consistent with genetic linkage to 5q14-21 (Pieke-Dahl
et al. 2000). We had previously obtained informed con-
sent and had extracted DNA from peripheral whole
blood of the study subjects according to standard con-
ditions (Puregene). Patients with a clinical diagnosis of
USH2 were ascertained through physician referral and
self-referral. The study was conducted with the approval
of the Boys Town National Research Hospital (BTNRH)
institutional review board and met all ethical require-
ments and Health Insurance Portability and Accounta-
bility Act (HIPAA) standards. DNAs from an additional
152 unrelated patients with USH2 without an identifi-
able USH2A mutation on chromosome 1q41 were used
to screen for specific VLGR1 mutations identified from
either the mutation screen of the 10 probands with
USH2C or from those VLGR1 mutations reported else-
where (Nakayama et al. 2002).
Genomic VLGR1 PCR primer pairs were designed
and synthesized commercially (sequences available upon
request [Integrated DNA Technologies]). PCR used 20
ng genomic DNA, 0.2 mM primer, 2.5 mM MgCl2, 200
mM dNTP, in 1# PCR buffer with 0.5 units AmpliTaq
Gold (PE Biosystems) in 25 ml total volume. The initial
PCR cycle was 95C for 8 min and 30 s, followed by
40 cycles of 95C for 30 s, 55C for 30 s, and 72C for
1 min, with a final step of 70C for 10 min. BAC clones
spanning the VLGR1 genomic interval (CTD-2034A10,
exons 1–4; RP11-29K14, exons 2–42; RP11-62E10, ex-
ons 18–73; RP11-3B6, exons 51–83; CTD-2001K4, ex-
ons 84 and 85; CTD-2266L18, exons 86 and 87; RP11-
414H23, exons 88–90) were identified and used as a
control template to evaluate PCR-product heterodu-
plexes that were separated by DHPLC; these clones were
also used in direct PCR sequence analysis.
Three human VLGR1 mRNA isoforms are expressed
(VLGR1a, VLGR1b, and VLGR1c), of which only
VLGR1b and VLGR1c isoforms are expressed in mouse
(McMillan et al. 2002) (fig. 2). Of 72 nucleotide changes
discovered in VLGR1 (see table A [online only]), 4 mu-
tations would prematurely terminate VLGR1a and
VLGR1b protein translation (fig. 1). The VLGR1
6901CrT (Q2301X) and 8716-17insAACA (I2906FS)
mutations were found in repulsion exclusively in the
members of family 1848 who were affected with USH2C
(fig. 1a and 1c). Family 964 (with USH2C) was found
to segregate a maternal VLGR1 8790delC (M2931FS)
mutation (fig. 1b). A paternal 19-bp deletion (18732–
18750del19bp; T6244X) segregates appropriately with
the phenotype in family 735 (fig. 1d). Families 735 and
964 have been shown elsewhere to genetically link to
the 5q14.3-q21 region, with all affected siblings sharing
family-specific 5q 14.3-q21 haplotypes (Pieke-Dahl et al.
2000). No other potential VLGR1 variant was found
associated with the maternal allele of family 735; how-
ever, a paternal IVS75-15GrA mutation absent in 190
control chromosomes was found segregating with the
phenotype in family 964 (data not shown). It remains
to be determined whether and how IVS75–15GrA af-
fects VLGR1 expression. Screening for USH2C muta-
tions in 152 patients with USH2 revealed the Q2301X
mutation in two other unrelated patients with sporadic
USH2. Table 1 presents a clinical summary of all patients
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Table 1
Clinical Summary of Patients with USH2C Harboring VLGR1 Mutations
Family No. and
Individual No.
Severity of
Hearing Loss
Age at
RP Diagnosis
(years) Sex RP Symptoms VLGR Mutation(s)
735a:
1 Moderate-severe 27b Female Typical T6244X/occult
5 Moderate-severe 25 Female NA T6244X/occult
6 Moderate-severe 20 Female NA T6244X/occult
7c Moderate-severe 19 Female NA T6244X/occult
964d:
1 Moderate-severe 24 Female Typical M2931FS/occult
3 Moderate-severe 21 Female Typical M2931FS/occult
4 Moderate-severe 33 Female Mild M2931FS/occult
1127:
1 Moderate-severe 42 Female Typical Q2301X/occult
1848a:
1 Moderate-severe 32b Female NA Q2301X/I2906FS
2 NA 29 Female NA Q2301X/I2906FS
3 NA 29 Female NA Q2301X/I2906FS
4 NA 21 Female NA Q2301X/I2906FS
2684e:
1 Moderate-severe 17 Female NA Q2301X/Q2301X
NOTE.—NA p not available.
a United States, country of origin.
b The RP diagnosis in the oldest child led to the earlier age at RP diagnosis in the other siblings.
c Reported that loud sounds caused nausea and, occasionally, dizziness.
d Sweden, country of origin.
e Consanguineous.
with USH2C who harbor VLGR1 mutations. A total of
five independent probands with USH2 and eight affected
siblings were found to bear pathological VLGR1 muta-
tions. Two probands have pathological mutations iden-
tified in both alleles; three occult mutant alleles eitherhave
escaped detection by the methodology employed, lie in
unscreened regions of the gene, or have been detected but
not appreciated as disease alleles. None of the four
VLGR1 mutations was observed in 190 control chro-
mosomes. These results establish VLGR1 as the USH2C
gene and implicate the protein, which is the largest cell
surface receptor known (McMillan et al. 2002), in the
pathogenesis of USH2.
Because the USH2 phenotype manifests cochlear and
retinal defects, we wanted to determine if any of the
three VLGR1 isoforms were tissue specific in these or-
gans (fig. 3a and 3b). We performed semiquantitative
RT-PCR by use of total RNA isolated from nine human
fetal tissues. Primer pairs for the human isoforms
VLGR1a, VLGR1b, and VLGR1c have been described
elsewhere (McMillan et al. 2002). Total RNA from three
human tissues (fetal brain, fetal liver, and placenta) was
purchased from Clontech. For cDNA synthesis, total
RNA was treated with DNase I (Invitrogen), according
to the manufacturer’s conditions, and random-primed
in a volume of 250 ml from 3.1 mg total RNA using 4
pmol random hexanucleotides, 10 mM Tris-HCl, pH
8.3, 50 mM KCl, 0.01% (v/w) gelatin, 5 mM MgCl2, 1
mM DTT, 95 U RNAguard (Pharmacia), and 2,500 U
MMLV reverse transcriptase (Invitrogen). Semiquanti-
tative RT-PCRs were performed by sampling 50 ml RT-
PCR reactions at the 25th, 30th, 35th, and 40th cycle.
PCR reactions included 87 ng of randomly primed
cDNA, 11.2 pmol of each primer, 10 mM Tris-HCl, pH
8.3, 50 mM KCl, 0.01% gelatin, 2.5–3 mMMgCl2, 160
mM of each dNTP, and 1.75 U Taq DNA polymerase
(Invitrogen) under the following conditions: 92C for 4
min, followed by 40 cycles of 95C for 30 s, 50C / 55C
for 30 s, and 72C for 1 min, with a final step at 72C
for 10 min. RT-PCR results show expression of all three
VLGR1 isoforms from fetal retina and cochlea, confirm-
ing the EST expression profile of VLGR1. High relative
expression in fetal brain and spinal cord confirms the
neuronal expression of VLGR1 (McMillan et al. 2002)
(fig. 3a and 3b). Although there appears to be a consis-
tent difference in the amount of VLGR1a, VLGR1b, and
VLGR1c RT-PCR products amplified from different tis-
sues, no apparent tissue-specific differences in the rela-
tive abundance between the three isoforms was seen in
any of the fetal tissues tested (fig. 3a and 3b). In addition,
we find the relative amount of the VLGR1a and
VLGR1b isoforms to be roughly equal as judged by RT-
PCR, which is in contrast to an approximately fourfold
difference in expression of the VLGR1b isoform over
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Figure 2 Domain structure of VLGR1/MASS1 isoforms. Conceptual translation of VLGR1b mRNA reveals a protein with a large
ectodomain with 35 Calx-b domains, 1 LamG/TspN/PTX homology domain (Beckmann et al. 1998), 7 EAR/EPTP repeats forming a putative
b-propeller folding domain (Scheel et al. 2002; Staub et al. 2002), a GPS, a B-family 7TM domain, a putative intracellular tail with multiple
potential serine phosphorylation sites, and a putative PDZ-binding COOH-terminal end (McMillan et al. 2002). The PTX domains of VLGR1
and the USH2A protein usherin are most similar to one another, with a BLASTP score of 2e-09. The locations of human USH2C (yellow) and
febrile-seizure (FS; gray)–associated mutations are shown on VLGR1a, VLGR1b, and VLGR1c isoforms. The mouse audiogenic reflex seizure
model Frings and the age-related hearing loss model BUB/BnJ are both homozygous for the V2250FS mutation and are noted on Mass1.1,
Mass1.2, and Mass1.3 isoforms (Skradski et al. 2001).
the VLGR1a isoform previously observed in human fetal
kidney, brain, and lung (McMillan et al. 2002). One
explanation for this disparity could be the way the RT-
PCR of the VLGR1a and VLGR1b isoforms was per-
formed, as the study byMcMillan et al. (2002) amplified
VLGR1a and VLGR1b in multiplex, whereas we chose
to amplify them in separate reactions because of a sig-
nificant difference in the TMs of the sense primers.
The VLGR1b and VLGR1c isoforms differ by 83 bp
as a result of the alternative exon 31 donor splicing
(Skradski et al. 2001; McMillan et al. 2002). A mouse
Vlgr1 mutation in exon 31 (7009delG; V2250FS ) is re-
sponsible for the monogenic audiogenic seizure suscep-
tible (MASS) phenotype (Skradski et al. 2001). The
Vlgr17009delG (Vlgr1Mass1) mouse allele mutates both mouse
Vlgr1b and Vlgr1c splice isoforms, whereas the human
exon 31 VLGR1 mutation (Q2301X), in addition to the
other three USH2C mutations, affects VLGR1b (figs. 2
and 3). To determine if species-specific differences in the
VLGR1b and VLGR1c isoforms might help to explain
theVLGR1mutant phenotypes, RT-PCRofVLGR1band
VLGR1c isoforms frommouse and human fetal RNAwas
performed. For RT-PCR of the VLGR1b and VLGR1c
isoforms, random-primed total mRNA from human and
mouse fetal brain RNA (Clonetech) was reverse tran-
scribed with Superscript III (Invitrogen), according to
standard conditions, and PCR with AmpliTaq Gold (PE
Biosystems) was as described for genomic PCR ampli-
fication, except that the amount of MgCl2 was 3.0 mM.
Amplification primers for the mouse Vlgr1b and Vlgr1c
isoforms were as follows: sense 5′-CGAACTGGAGGA
ACATTTGCAG-3′ and antisense 5′-GCAGACACGTT
CACCCAAGTTC-3′. Cloning and sequencing of
VLGR1b and VLGR1c RT-PCR products from both hu-
man and mouse confirm the evolutionarily conservation
of the alternative exon 31 splice donor sites in both
species (data not shown). It is not surprising that, al-
though the VLGR1b messages of human and mouse
share 81% sequence identity overall, the last 113 bp of
exon 31 are 100% conserved at the DNA level, indi-
cating that the sequence context of the mRNA in this
region is critically important, perhaps defining a critical
cis element necessary for alternative mRNA processing.
A comparison of RT-PCR products from fetal human
and mouse brain revealed a difference in the relative
abundance of VLGR1b and VLGR1c isoforms, indicat-
ing a species-specific difference in mRNA processing
through the alternative exon 31 donor sites (fig. 3c).
These results suggest that isoform-specific mutations in
VLGR1, either alone or in combination with a specific
difference in mRNA processing, may underlie the man-
ifestation of phenotype in these species.
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Figure 3 RT-PCR of VLGR1 mRNA splice forms from human and mouse fetal tissue. Human fetal tissues from left to right: eye (Ey),
cochlea (Co), brain (Br), kidney (Ki), colon (Cl), stomach (St), lung (Lu), liver (Li), spinal cord (Cr), muscle (Mu), tongue (To), and adult
placenta (Pl). A, The relative locations of the human Q2301X and the Frings and BUB/BnJ mouse V2250FS mutations to the alternative donor
site that differentiates the VLGR1b and VLGR1c splice isoforms. These isoforms differ by 83 bp because of the alternative use of a 5′ splice-
donor site in exon 31 (Skradski et al. 2001; McMillan et al. 2002). Expression from eye and cochlear tissue is less intense at 30 cycles of RT-
PCR than from brain and spinal cord. At 40 cycles, all tissues but liver and placenta show VLGR1 expression of similar relative intensities for
VLGR1c, compared with VLGR1b (fig. 2b; data not shown). B, The location of the VLGR1a 5′ start site, relative to the exon 65 3′ splice
acceptor of VLGR1b. RT-PCR results at 30 cycles for VLGR1a and VLGR1b splice forms show a similar tissue distribution to that in figure
2a, as well as similar relative intensities. All RNAs were positive for D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (data not shown).
C, A comparison of VLGRb and VLGR1c concentration in human and mouse reveals a species-specific difference in the relative abundance of
these isoforms, which were amplified from fetal brain mRNA, indicating a difference in the use of the alternate exon 31 donor sites between
species.
In situ hybridization of mouse embryo sections had
shown Vlgr1 expression concentrated in the ventricular
zone where neural progenitor cells reside during embry-
onic neurogenesis, suggesting that the Vlgr1b andVlgr1c
isoforms play a role in the development of the murine
CNS (McMillan et al. 2002). This idea is strengthened
by the association of the MASS phenotype with the
Vlgr1 mutant allele (Skradski et al. 2001). The Vlgr1
mouse ortholog includes in its open reading frame three
additional and distinct mRNAs previously character-
ized as isoforms of the mouse Mass1 gene (Mass1.1,
Mass1.2, and Mass1.3) on mouse chromosome 13
(Skradski et al. 2001) (fig. 2). The Frings mouse has not
been reported to have deficient hearing or vision; how-
ever, no histological or electrophysiological data have
been published that explicitly rule out such possibilities.
In addition to Frings, the BUB/BnJ inbred mouse was
also found to be a Vlgr1Mass1 homozygote, and it exhibits
the MASS phenotype until a progressive age-related
hearing loss (AHL) phenotype manifests in this strain
by 3 wk of age (Skradski et al. 2001). BUB/BnJ is one
of several inbred mouse strains exhibiting AHL (Zheng
et al. 1999). The variable severity and progression of
hearing loss in many AHLmouse strains, including BUB/
BnJ, is influenced by a major modifier locus on mouse
chromosome 10 (ahl, also the modifier-of-deaf-waddler
locus, mdfw). Both ahl and mdfw are caused by the
Cdh23753GrA splicing mutation, a synonymous transition
of the last nucleotide of exon 7 (Noben-Trauth et al.
2003). It remains to be determined if the early onset of
hearing loss in BUB/BnJ is influenced by the Vlgr1Mass1
mutation, as has been shown for other AHL “acceler-
ating alleles” in combination with Cdh23753A (Noben-
Trauth et al. 2003). It should be noted that BUB/BnJ is
also homozygous for rd1, a mutation in the Pde6b gene
that results in early photoreceptor-cell apoptosis because
of a lack of cGMP phosphodiesterase activity. The fact
that BUB/BnJ carries homozygous mutations in Pde6b
(rd1), Cdh23 (ahl, mdfw), and Vlgr1 (Mass1) suggests
caution should be used in interpreting the phenotypic
effects of these genes in this mouse strain.
The VLGR1 protein belongs to a 33-member sub-
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group of the large N-terminal family B (LNB) seven-
transmembrane (7TM) receptors. Of the 33 LNB 7TM
members, 32 are orphan receptors and only a few have
demonstrated specific G-protein signaling (Foord et al.
2002). All LNB 7TM members, including VLGR1, have
a G-protein–coupled proteolysis site (GPS); cleavage at
this site is thought to be a requirement for the proper
expression of this class of 7TM receptors on the cell
surface (Krasnoperov et al. 2002). VLGR1 may func-
tion, like other LNB 7TMmembers, as a natural protein
chimera, with an extracellular cell-adhesion subunit and
a canonical G-protein–coupled receptor subunit that are
linked by noncovalent interactions (Krasnoperov et al.
2002). The possible function of VLGR1 might be best
explored by trying to predict the functions of the two
putative subunits separately.
The C-terminal residues of VLGR1 correspond to the
consensus motif that is recognized as a ligand for the
class I subfamily of PDZ domains (PDZ-binding inter-
face [PBI] [Nikkila et al. 2000; Hung and Sheng 2002]).
Interestingly, the C-termini of cadherin 23, protoca-
dherin 15, harmonin, and SANS, all proteins with mu-
tations that cause the USH1 phenotype, have class I PBIs.
An interaction through the 2nd PDZ domain of har-
monin and the C-terminal PBI ligand of cadherin 23 has
been independently confirmed (Boeda et al. 2002; Sie-
mens et al. 2002). Colocalization of harmonin and SANS
in transfected HeLa cells suggests that these proteins also
interact, perhaps through a PDZ-PBI interaction (Weil
et al. 2003). The fact that all USH1 protein mouse mu-
tants, including the nonmuscle myosin VIIa, which also
has a protein interaction with harmonin, phenotypically
present with defects in hair cell stereocilia development
suggests that these proteins function as a macromolec-
ular complex necessary to shape and maintain the ster-
eocilia as an organized cohesive unit (Boeda et al. 2002;
Siemens et al. 2002; Weil et al. 2003). It remains to be
determined whether one or more of the three PDZ do-
mains of harmonin—or other PDZ domain–bearing pro-
tein—have a high-affinity interaction with the PBI of
VLGR1.
The very large extracellular portion of VLGR1b has
a total of 35 CalX-b modules (fig. 2), named for the
homology shared between the regulatory domains of
Na/Ca2 exchanger proteins and the cytoplasmic por-
tion of integrin-b4 (Schwarz and Benzer 1997;McMillan
et al. 2002). Portions of the extracellular domain of
VLGR1a that include a subset of the CalX-b domains
bind Ca2 and other cations (Nikkila et al. 2000). Be-
cause of the extensive CalX-b modules, one might pos-
tulate that the molecule acts as an extracellular Ca2
sink, as an extracellular Ca2 monitor sensitive to the
regulation of intra- and extracellular Ca2 trafficking,
or in Ca2-dependent cell adhesion. Disruption of nor-
mal Ca2 metabolism is known to affect both hearing
and vision. For example, mutations in the plasma
membrane Ca2 ATPase pump Atp2b2 (PMCA2) cause
the deaf waddler (dfw) phenotype in mice (Kozel et al.
1998; Street et al. 1998). It has been postulated that the
murine ahl gene (mdfw, Cdh23753A) acts epistatically to
cause an age-dependent hearing loss through an inter-
action between the Ca2-extruding PMCA2 channel and
the calcium-dependent homotypic cell-adhesion prop-
erties of the cadherin 23 protein (Noben-Trauth et al.
1997, 2003). Furthermore, a functional interaction has
been postulated between PMCA2 and the sodium bi-
carbonate cotransporter, NBC3, at the photoreceptor
synapse, as the loss of H buffering by NBC3 causes
retinal dystrophy (and hearing loss) in NBC3 knock-out
mice (Bok et al. 2003). The possibility that calcium ho-
meostasis is involved in USH2C is especially intriguing
in light of the observation that the Ca2-channel–block-
ing drug, diltiazem, is protective against noise-induced
hearing loss (Maurer et al. 1998; Heinrich et al. 1999).
However, there is conflicting evidence about whether dil-
tiazem is neuroprotective for the retina, since none of
the animal models tested had RP resulting from a cal-
cium metabolism defect (Frasson et al. 1999; Pasantes-
Morales et al. 2002; Pawlyk et al. 2002).
The large VLGR1b ectodomain has two recognized
potential protein-interaction domains, LamG/TspN/
PTX (Beckmann et al. 1998) and EAR/EPTP (Scheel et
al. 2002; Staub et al. 2002) (fig. 2). It has been suggested
that the multiple Ca2-binding CalX-bmodules may me-
diate the protein-protein interactions of these two do-
mains (McMillan et al. 2002). The EAR/EPTP motif
occurs as a repeated set of domains that together are
postulated to form a seven-bladed-propeller structure
that, in other proteins, acts as a highly specific receptor
(Pons et al. 2003). Probable ligands for the EAR/EPTP
domain of VLGR1 would be extracellular or cell-ad-
hesion proteins. Usherin, the product of the USH2A
gene, is a known extracellular basement-membrane pro-
tein (Bhattacharya et al. 2002). When usherin is defec-
tive, the phenotype is remarkably similar to that seen in
patients with inactivated VLGR1. Immunolocalization
of usherin to the perinurium of the spiral ganglion cells
of the cochlea (Bhattacharya et al. 2002) and the likely
neuronal localization of the VLGR1 receptor indicates
that VLGR1 and usherin may colocalize in specific sub-
cellular compartments. Furthermore, the significant ho-
mology between the LamG/TspN/PTXmotifs of VLGR1
(fig. 2) and usherin indicates that the two proteins may
share an affinity for a common binding partner, rein-
forcing the hypothesis of an interaction between these
proteins. Whether usherin is the extracellular ligand or
another yet-to-be-identified USH2 protein remains to
established.
Because VLGR1 is expressed as at least three different
isoforms in the human, questions arise as to which of
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the isoforms is responsible for USH2C and, as a cor-
ollary, whether mutations involving other isoforms cause
a different phenotype, especially a seizure disorder. The
USH2C mutations we have observed all involve isoform
VLGR1b, but not isoform VLGR1c. The Frings muta-
tion affects both VLGR1b and VLGR1c. We specifically
asked all of the patients with USH2C in our study about
seizures of any type and received uniformly negative re-
sponses. It is plausible to hypothesize that the Frings
seizure disorder is primarily due to mutations affecting
the VLGR1c isoform. Whether a functional protein is
encoded by VLGR1c will be important in helping to
determine whether the disparity in phenotype between
human and mouse VLGR1 mutants are governed by
species-specific differences in VLGR1 function, the in-
activation of a subset of VLGR1 isoforms, or a com-
bination of the two. The fact that the VLGR1 S2832X
and S2764P mutations (isoform VLGR1b) segregate in
families with both febrile and afebrile seizures (FEB4
[MIM 604352]) suggests a causal relationship between
human seizures and VLGR1. But the relative low fre-
quency of FEB4-associated mutations, the lack of a sig-
nificant association between VLGR1 SNPs and FEB4,
and the lack of any self-reported seizure-related phe-
notype in our USH2C patients suggest that VLGR1b is
not a significant contributor to any seizure disorder (Na-
kayama et al. 2002).
All 13 patients with USH2C and VLGR1 mutations
are female, a highly significant deviation from expectation
( , Fisher’s exact test). The biologic significance,P ! .002
if any, of this observation can only be speculated on.
Although some selection bias could conceivably play a
role, it is difficult to understand why the shift in sex ratio
is so extreme. A likely explanation is that males are being
excluded from the sample: the male phenotype might be
more severe, possibly lethal; it could be associated with
some other hearing-/vision-loss syndrome; or the phe-
notype could be very mild or nonexistent. Nonetheless,
the possibility that an endocrine-based component could
influence the Usher syndrome phenotype as a modifier of
VLGR1 expression and/or protein function is intriguing.
Mutations in VLGR1 do not seem to be responsible for
a large proportion of the USH2 cases in our sample, de-
spite the fact that the gene is large and one might have
expected otherwise. The possibility of male lethality could
explain the apparently low contribution of USH2C mu-
tations to the total USH2 mutational load.
The discovery of USH2C-associated VLGR1 muta-
tions poses several interesting and important questions
regarding the etiology of USH2. Localization and func-
tional studies, in addition to thorough genetic screening
for additional VLGR1 mutations, will be needed to elu-
cidate the role of VLGR1 in the development, mainte-
nance, and function of vision and hearing. Furthermore,
its capacity as a putative G-coupled receptor makes it
a legitimate target in the search for possible therapeu-
tics that may have a broad impact on all types of Usher
syndrome.
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